Physical AI News (Japan)

Physical AI, robotics and compute — reported from Japan.

日本語
· Funding· 日本語で読む

Remedy Robotics raises $62 million to develop a cardiovascular and endovascular treatment robot

Remedy Robotics raised $62 million in a Series B round. The funds will support clinical trials of the N1 System, efforts toward FDA approval and other initiatives. The N1 System is in development and is not currently for sale or clinical use.

Key facts

  • Remedy Robotics announced on Nov. 16, 2026, that it raised $62 million in a Series B round.
  • DCVC led the funding round, with participation from UC Investments, Skip Capital, Hostplus and others.
  • The company plans a key clinical trial with the University of California and is pursuing FDA approval for neurovascular treatments.
  • The N1 System is described as featuring machine-learning analysis of preoperative images, advance procedure simulation and real-time 3D-2D image registration.
  • The N1 System is in development and is not for sale or clinical use in any region.

What happened

Remedy Robotics announced on Nov. 16, 2026, that it raised $62 million in a Series B round to advance development of the N1 System, a robot for cardiovascular and neurovascular endovascular procedures. DCVC led the round, with participation from UC Investments, Skip Capital, Hostplus and existing investors Build Collective, Blackbird, Divergent Capital and KdT Ventures. The funds will be used to plan a key clinical trial with the University of California, pursue FDA approval for neurovascular treatments and deploy N1 System prototypes.

Why it matters

The funding was announced as support to advance the N1 System toward clinical trials and FDA approval. Remedy Robotics says the system is still in development and is not for sale or clinical use. For health care providers, therefore, evaluation in clinical trials and its regulatory status—not the concepts of remote operation or autonomy—will determine the conditions for adoption.

Analysis

The stated uses for the $62 million include clinical trials, efforts toward FDA approval and prototype deployment. The company did not disclose how the funding will be allocated among these areas, so the amount alone does not show which will receive priority. The news is not about expanding sales of a finished medical device, but about funding to move the N1 System, which is in development, into clinical evaluation and regulatory review. The company also plans to deploy prototypes across its network of clinical partners, while stating that the system is not currently for sale or clinical use. A related article by Physical AI News, IEEE Spectrum reports on the verification status of Remedy Robotics' remote stroke surgery robot, covered efforts to use robots for stroke surgery performed remotely. It noted that the article's subject alone was insufficient to determine actual operating conditions or clinical evaluation; the latest funding announcement likewise does not provide clinical results that address those questions. Across both articles, the key issue is not the concept of remote operation itself, but the conditions and evaluation metrics under which performance and safety will be tested in the planned trials. The N1 System's design links preoperative image analysis, procedure simulation, intraoperative 3D-2D image registration and robotic procedures. This indicates that it is being developed as a system incorporating image processing and procedure planning, not just as a standalone robotic mechanism. However, the announcement does not say at what stage each of the proposed operating modes—in-hospital, remote and autonomous—will be included in clinical trials, or define the scope of autonomy for each function. Clinical evaluation is likely to focus not only on the robot's movements but also on the reproducibility of the entire process, including image recognition and registration. Points to watch include the planned trial's start date, number of patients, evaluation criteria, timing of an FDA submission, scope of autonomous functions and safety measures. The announcement provides no specifics on these matters. The size of the funding round and the concept of remote operation should not be equated with clinical efficacy or the outlook for approval; progress in trials and regulation should be assessed separately.

Details

According to the company, the N1 System is a robotic platform and software suite that uses machine learning to analyze preoperative images, simulate procedures in advance and perform real-time 3D-2D image registration. It is designed for in-hospital, remote and autonomous operation. The company is developing capabilities to complete endovascular procedures robotically, as well as autonomous functions. The company is planning a key clinical trial within the University of California network. It says the N1 System is in development and is not for sale or clinical use in any region.

Sources

Translated from the Japanese original: /news/remedy-robotics-shinketsu-kan-kekkannai-chiryou-robotto-no-k-bf953a. The Japanese version is authoritative if they differ.